A Trans-amplifying RNA Vaccine Strategy for Induction of Potent ...
WEBJan 8, 2020 · Here, we present a potent RNA vaccine approach based on a novel bipartite vector system using trans-amplifying RNA (taRNA). The vector cassette encoding the vaccine antigen originates from an alphaviral self-amplifying RNA (saRNA), from which the replicase was deleted to form a transreplicon.
BioNTech | mRNA: a drug class of its own
WEBTrans-amplifying mRNA (taRNA) This technology is an advancement of the saRNA platform. By separating the target mRNA to be amplified from the replicase encoding mRNA, we can develop more applications.
A trans-amplifying RNA simplified to essential elements is highly ...
WEBJun 7, 2023 · Trans-amplifying RNA (taRNA) is a split-vector derivative of self-amplifying RNA (saRNA) and a promising vaccine platform. taRNA combines a non-replicating mRNA encoding an alphaviral replicase and a transreplicon (TR) RNA coding for the antigen.
A trans-amplifying RNA simplified to essential elements is highly ...
WEBJun 7, 2023 · This work presents the improvement of trans-amplifying RNA (taRNA), a bipartite vector system aiming to accelerate RNA vaccine adaptation by using an mRNA-encoded alphaviral replicase that amplifies minimal amounts of …
WEBTrans-amplifying RNA (taRNA) is a split-vector derivative of self-amplifying RNA (saRNA) and a promising vaccine plat-form. taRNA combines a non-replicating mRNA encoding an alphaviral replicase and a transreplicon (TR) RNA coding for the antigen.
A Bivalent Trans-Amplifying RNA Vaccine Candidate Induces …
WEBAug 23, 2022 · The bivalent taRNA vaccination was able to generate CHIKV- and RRV-specific antibodies. However, compared to the respective single vaccinations, the endpoint titers were reduced. In addition to the total antibody titers, the bivalent vaccination also showed reduced neutralizing antibody responses.
mRNA-based cancer therapeutics - Nature Reviews Cancer
WEBJun 13, 2023 · As a transient carrier of genetic information, the in vitro transcribed mRNA, including conventional mRNA, self-amplifying mRNA (saRNA), trans -amplifying mRNA (taRNA) and circular mRNA...
mRNA vaccines: the most recent clinical applications of synthetic …
WEBApr 15, 2022 · During the SARS-CoV-2 pandemic, mRNA vaccines, including mRNA-1273 and BNT 162b2, were developed by Moderna and Pfizer-BioNTech, respectively. They have been developed at an unprecedented speed in the history of vaccine development.
A taRNA vaccine candidate induces a specific immune response …
WEBJun 14, 2022 · Using a prime-boost schedule, the vaccine candidate induced potent CHIKV-specific humoral and cellular immune responses in vivo in a mouse model. Notably, mice were protected against a high-dose CHIKV challenge infection with two vaccine doses of only 1.5 μg RNA.
BioNTech Announces Positive Topline Phase 2 Results for mRNA ...
WEBJul 30, 2024 · BNT111 is an mRNA-based off-the-shelf cancer immunotherapy candidate for intravenous administration encoding a fixed set of four non-mutated melanoma-associated antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) delivered as …